REFRACTORY/RELAPSE ACUTE MYELOID LEUKEMIA
Clinical trials for REFRACTORY/RELAPSE ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY/RELAPSE ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY/RELAPSE ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental CAR-T therapy takes on tough leukemia
Disease control Recruiting nowThis early-stage trial is testing a new type of CAR-T cell therapy, called CT0890B, for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses donor-derived immune cells that are engineered to target a protein called NKG2DL on …
Matched conditions: REFRACTORY/RELAPSE ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental ceramide therapy takes on tough leukemia
Disease control Recruiting nowThis early-stage trial tests a new drug called C6 ceramide nanoliposome (Ceraxa) in 15 adults with acute myeloid leukemia that has come back or not responded to treatment. The drug is given by IV twice a week, and the main goal is to check safety and find the right dose. It is to…
Matched conditions: REFRACTORY/RELAPSE ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: Keystone Nano, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC